{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:17:22Z","timestamp":1788556642060,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.hoc.2016.11.010","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T16:52:19Z","timestamp":1490287939000},"page":"273-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["T-cell Prolymphocytic Leukemia"],"prefix":"10.1016","volume":"31","author":[{"given":"Amit","family":"Sud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dearden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7823","key":"10.1016\/j.hoc.2016.11.010_bib1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(73)93135-8","article-title":"Prolymphocytic leukaemia of B and T\u00a0cell type","volume":"2","author":"Catovsky","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2016.11.010_bib2","series-title":"World Health Organization classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"12","key":"10.1016\/j.hoc.2016.11.010_bib3","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood.V78.12.3269.3269","article-title":"Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia","volume":"78","author":"Matutes","year":"1991","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.010_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2162-3619-1-7","article-title":"Pediatric T-cell prolymphocytic leukemia with an isolated 12(p13) deletion and aberrant CD117 expression","volume":"1","author":"Bellone","year":"2012","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.010_bib5","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/pbc.25336","article-title":"A\u00a0pediatric case of T-cell prolymphocytic leukemia","volume":"62","author":"Mitton","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.010_bib6","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1097\/MPH.0000000000000317","article-title":"A\u00a0gamma\/delta T-cell receptor prolymphocytic leukemia and CD4-\/CD8- double-negative immunophenotype in a pediatric patient","volume":"37","author":"Moser","year":"2015","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.010_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.2014.56.5101","article-title":"Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French National Registry of Primary Immune Deficiencies","volume":"33","author":"Suarez","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2016.11.010_bib8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00277-003-0697-y","article-title":"T-cell prolymphocytic leukemia with autoimmune manifestations in Nijmegen breakage syndrome","volume":"82","author":"Michallet","year":"2003","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.hoc.2016.11.010_bib9","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.4065\/80.12.1660","article-title":"Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment","volume":"80","author":"Ravandi","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.hoc.2016.11.010_bib10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaad.2006.04.060","article-title":"T-cell prolymphocytic leukemia: an aggressive T\u00a0cell malignancy with frequent cutaneous tropism","volume":"55","author":"Magro","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.hoc.2016.11.010_bib11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jaad.2007.02.034","article-title":"Skin involvement in T-cell prolymphocytic leukemia","volume":"57","author":"Herling","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.010_bib12","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1309\/AJCPOBDP2OQAJ5BR","article-title":"Mycosis fungoides. Report of the 2011 Society for Hematopathology\/European Association for Haematopathology Workshop","volume":"139","author":"Song","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.010_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0165-4608(97)00410-X","article-title":"Abnormalities of chromosomes 8,\u00a011, 14, and X in T-prolymphocytic leukemia studied by fluorescence in\u00a0situ hybridization","volume":"103","author":"Maljaei","year":"1998","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.010_bib14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood.V92.2.368","article-title":"Transgenic mice for MTCP1 Develop T-Cell Prolymphocytic Leukemia","volume":"92","author":"Gritti","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2016.11.010_bib15","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1073\/pnas.95.7.3885","article-title":"Deregulated expression of TCL1 causes T\u00a0cell leukemia in mice","volume":"95","author":"Virgilio","year":"1998","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.010_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1097-2765(00)00039-3","article-title":"The protooncogene TCL1 is an Akt kinase coactivator","volume":"6","author":"Laine","year":"2000","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.010_bib17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0165-4608(03)00161-4","article-title":"High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia","volume":"147","author":"Costa","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"issue":"3","key":"10.1016\/j.hoc.2016.11.010_bib18","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/gcc.1141","article-title":"A\u00a0complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia","volume":"31","author":"Soulier","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.010_bib19","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood-2007-06-095570","article-title":"Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia","volume":"111","author":"Le Toriellec","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2016.11.010_bib20","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.010_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2013.271","article-title":"Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia","volume":"28","author":"Bellanger","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.010_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjh.13952","article-title":"Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia","volume":"173","author":"Lopez","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.010_bib23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2007-07-101519","article-title":"High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia","volume":"111","author":"Herling","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2016.11.010_bib24","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.1997.15.7.2667","article-title":"Treatment of T-cell prolymphocytic leukemia with human CD52 antibody","volume":"15","author":"Pawson","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.010_bib25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cncr.11551","article-title":"Phase II study of alemtuzumab in chronic lymphoproliferative disorders","volume":"98","author":"Ferrajoli","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.010_bib26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.2002.20.1.205","article-title":"Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed","volume":"20","author":"Keating","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.010_bib27","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2016.11.010_bib28","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype","volume":"12","author":"Mercieca","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.010_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0002-9343(91)80164-H","article-title":"Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia","volume":"90","author":"Kantarjian","year":"1991","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.hoc.2016.11.010_bib30","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1200\/JCO.2007.14.1986","article-title":"Phase I trial of nelarabine in indolent leukemias","volume":"26","author":"Gandhi","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2016.11.010_bib31","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.27972","article-title":"Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia","volume":"119","author":"Hopfinger","year":"2013","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.hoc.2016.11.010_bib32","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1182\/blood-2011-08-372854","article-title":"Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route","volume":"118","author":"Dearden","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.010_bib33","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1365-2141.2010.08134.x","article-title":"Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study","volume":"149","author":"Krishnan","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2016.11.010_bib34","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/leu.2011.304","article-title":"Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium","volume":"26","author":"Wiktor-Jedrzejczak","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2016.11.010_bib35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ejh.12430","article-title":"Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French Society for Stem Cell Transplantation (SFGM-TC)","volume":"94","author":"Guillaume","year":"2015","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.010_bib36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bbmt.2009.11.021","article-title":"Allogeneic hematopoietic cell transplant for prolymphocytic leukemia","volume":"16","author":"Kalaycio","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"32","key":"10.1016\/j.hoc.2016.11.010_bib37","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1200\/JCO.2009.22.6688","article-title":"Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms","volume":"27","author":"Ravandi","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.010_bib38","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjh.13175","article-title":"Bendamustine is effective in T-cell prolymphocytic leukaemia","volume":"168","author":"Herbaux","year":"2015","journal-title":"Br J Haematol"},{"issue":"293","key":"10.1016\/j.hoc.2016.11.010_bib39","doi-asserted-by":"crossref","first-page":"293ra102","DOI":"10.1126\/scitranslmed.aaa5079","article-title":"Epigenetic therapy overcomes treatment resistance in T-cell prolymphocytic leukemia","volume":"7","author":"Hasanali","year":"2015","journal-title":"Sci Transl Med"},{"issue":"22","key":"10.1016\/j.hoc.2016.11.010_bib40","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","article-title":"The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in\u00a0vitro and in\u00a0vivo","volume":"116","author":"Weston","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2016.11.010_bib41","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","article-title":"How I treat prolymphocytic leukemia","volume":"120","author":"Dearden","year":"2012","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:04:04Z","timestamp":1760184244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858816301782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0889858816301782"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2016.11.010","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-cell Prolymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2016.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}